<DOC>
	<DOCNO>NCT01576185</DOCNO>
	<brief_summary>These laboratory trial study development treatment mouse model acute myeloid leukemia ( AML ) use sample young patient AML . Studying tissue sample patient cancer laboratory may help doctor learn cancer well patient respond treatment .</brief_summary>
	<brief_title>Developing Treating Mouse Model Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine rate engraftment pediatric FMS-Like Tyrosine Kinase-3 ( FLT3 ) -internal tandem duplication ( ITD ) acute myeloid leukemia ( AML ) sample NOD scid gamma ( NSG ) mouse . II . To determine efficacy treatment FLT3-ITD xenograft tyrosine kinase inhibitor . OUTLINE : Human acute myeloid leukemia cell inject NSG mouse . Mice treat sorafenib quizartinib via gavage daily 28 day . Peripheral blood tissue sample collect biweekly weekly analyze presence human CD45+ CD33+ cell quantitative flow cytometry .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Cryopreserved human AML sample FLT3ITD sample high allelic ratio</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>